Drug profile · INN
mirdametinib
EZMEKLY
mirdametinib (EZMEKLY) is a dual specificity mitogen-activated protein kinase kinase 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — mirdametinib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
mirdametinib (EZMEKLY) is a dual specificity mitogen-activated protein kinase kinase 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
Primary target: Dual specificity mitogen-activated protein kinase kinase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is mirdametinib?
mirdametinib (EZMEKLY) is a dual specificity mitogen-activated protein kinase kinase 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for mirdametinib?
EZMEKLY is a marketed brand name for mirdametinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mirdametinib?
mirdametinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.